LEXX Key Statistics, Chart & Performance
The current stock price of LEXX is 1.12 USD. In the past month the price increased by 16.76%. In the past year, price decreased by -46.15%.
LEXX Latest News, Press Relases and Analysis
LEXX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.22 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 499.88B | ||
| MRK | MERCK & CO. INC. | 11.88 | 261.34B | ||
| PFE | PFIZER INC | 8.03 | 146.18B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.51 | 100.25B | ||
| ZTS | ZOETIS INC | 20.14 | 56.59B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.69 | 23.23B | ||
| VTRS | VIATRIS INC | 4.57 | 12.40B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.28 | 11.58B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.68 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.53B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.52B |
Related stock screener links
About LEXX
Company Profile
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Company Info
LEXARIA BIOSCIENCE CORP
100 - 740 Mccurdy Road
Kelowna BRITISH COLUMBIA V1X 2P7 CA
CEO: Christopher Bunka
Employees: 7
Phone: 12507656424
LEXARIA BIOSCIENCE CORP / LEXX FAQ
Can you describe the business of LEXARIA BIOSCIENCE CORP?
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Can you provide the latest stock price for LEXARIA BIOSCIENCE CORP?
The current stock price of LEXX is 1.12 USD. The price increased by 3.7% in the last trading session.
Does LEXX stock pay dividends?
LEXX does not pay a dividend.
How is the ChartMill rating for LEXARIA BIOSCIENCE CORP?
LEXX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is LEXX stock listed?
LEXX stock is listed on the Nasdaq exchange.
What sector and industry does LEXARIA BIOSCIENCE CORP belong to?
LEXARIA BIOSCIENCE CORP (LEXX) operates in the Health Care sector and the Pharmaceuticals industry.
LEXX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LEXX. When comparing the yearly performance of all stocks, LEXX is a bad performer in the overall market: 74.23% of all stocks are doing better.
LEXX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LEXX. The financial health of LEXX is average, but there are quite some concerns on its profitability.
LEXX Financial Highlights
Over the last trailing twelve months LEXX reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS decreased by -50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -168.9% | ||
| ROE | -205.08% | ||
| Debt/Equity | 0 |
LEXX Forecast & Estimates
8 analysts have analysed LEXX and the average price target is 5.44 USD. This implies a price increase of 385.71% is expected in the next year compared to the current price of 1.12.
For the next year, analysts expect an EPS growth of -50.04% and a revenue growth 69.94% for LEXX